Advanced bladder cancer is a difficult disease to treat in many patients.

For a long time, there was no major advance in first line treatment

Today, at an European Cancer conference in Madrid, there was a breakthrough announcement about a new combination for bladder cancer.

The combination of EV ( enfortumab vedotin) and Pembro ( Pembrolizumab) has shown dramatically better results in a clinical trial reported today.

The combination of EV+ Pembro will become first choice of treatment for Advanced bladder cancer now.

References

LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.